Dyadic International is on a high-growth trajectory, slashing costs by 40% and boosting productivity 80% with its animal-free recombinant human transferrin — a win that’s turbocharging their entire platform. They’re landing major deals, shipping to IBT Bioservices, and making initial sales in cultivated meat. By partnering with established distributors, they’re keeping their commercial team lean while expanding into food and nutrition with non-animal bovine chymosin and more royalties on the horizon. Fermbox Bio is scaling up too, showing multiple stages of commercialization. Dyadic is also leveraging optimized strains across research, cell culture, and new markets for faster validation and revenue. With near-term sales and externally funded biopharma programs generating critical data, they’re building a balanced, recurring-revenue business poised for strategic wins.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
